This site is intended for healthcare professionals only
This site is intended for healthcare professionals only
LMU Hospital, Munich, Germany
Martin Dreyling is Professor of Medicine and head of the lymphoma programme in the Department of Medicine III, LMU Hospital, Munich. He studied at the Universities of Düsseldorf, Giessen, Tübingen and Würzburg, and completed his clinical training at the Universities of Bonn, Münster, Göttingen and Munich. In addition, he was visiting scientist at the University of Chicago.
His scientific focus is on the molecular basis of malignant transformation, cell cycle dysregulation and secondary genetic alterations as well as biological prognostic factors in malignant lymphoma. He is also interested in innovative therapeutic approaches, including molecular targeted approaches like inhibitors of the B-cell receptor pathway and immunological approaches.
Professor Dreyling is coordinator of the European MCL Network and president elect of the German Lymphoma Alliance. He has co-authored numerous scientific papers, book chapters and abstracts in international peer-reviewed journals.
Lund University, Sweden
Mats Jerkeman is Professor in Clinical Oncology at Lund University, Sweden. Professor Jerkeman is also Chairman of the Nordic Lymphoma Group and the National Guidelines for Lymphoma, Sweden. His research focuses on improving the quality of life and survival of patients with malignant lymphomas. He completed his doctoral training at Lund University, Sweden.
Professor Jerkeman is the Coordinator of several ongoing clinical trials in diffuse large B-cell lymphoma and mantle cell lymphoma, and has also served as coordinator of the Swedish Lymphoma Register for many years. He is an Editor of the European Society of Medical Oncology Guidelines and a member of the American Society of Hematology. He has over 120 publications in peer-reviewed journals.
LMU Hospital, Munich, Germany
Martin Dreyling is Professor of Medicine and head of the lymphoma programme in the Department of Medicine III, LMU Hospital, Munich. He studied at the Universities of Düsseldorf, Giessen, Tübingen and Würzburg, and completed his clinical training at the Universities of Bonn, Münster, Göttingen and Munich. In addition, he was visiting scientist at the University of Chicago.
His scientific focus is on the molecular basis of malignant transformation, cell cycle dysregulation and secondary genetic alterations as well as biological prognostic factors in malignant lymphoma. He is also interested in innovative therapeutic approaches, including molecular targeted approaches like inhibitors of the B-cell receptor pathway and immunological approaches.
Professor Dreyling is coordinator of the European MCL Network and president elect of the German Lymphoma Alliance. He has co-authored numerous scientific papers, book chapters and abstracts in international peer-reviewed journals.
Lund University, Sweden
Mats Jerkeman is Professor in Clinical Oncology at Lund University, Sweden. Professor Jerkeman is also Chairman of the Nordic Lymphoma Group and the National Guidelines for Lymphoma, Sweden. His research focuses on improving the quality of life and survival of patients with malignant lymphomas. He completed his doctoral training at Lund University, Sweden.
Professor Jerkeman is the Coordinator of several ongoing clinical trials in diffuse large B-cell lymphoma and mantle cell lymphoma, and has also served as coordinator of the Swedish Lymphoma Register for many years. He is an Editor of the European Society of Medical Oncology Guidelines and a member of the American Society of Hematology. He has over 120 publications in peer-reviewed journals.
